(E)-3-(3,5-dimethylisoxazol-4-yl)acrylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-(3,5-dimethylisoxazol-4-yl)acrylic acid
• 英文别名: 3-(3,5-dimethyl-isoxazol-4-yl)-acrylic acid；(2E)-3-(3,5-dimethylisoxazol-4-yl)acrylic acid；(E)-3-(3,5-dimethyl-1,2-oxazol-4-yl)prop-2-enoic acid
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: BDTVMGBOXLTXBK-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS
  申请人：Aissaoui Hamed

  公开号：US20110281869A1

  公开（公告）日：2011-11-17

  The invention relates to novel tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.

  这项发明涉及新型四氢异喹啉衍生物及其作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括含有其中一种或多种化合物的药物组合物以及它们作为治疗或预防原虫感染的药物，尤其是疟疾的用途。
• [EN] TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS<br/>[FR] TÉTRAHYDROISOQUINOLÉINES EN TANT QU'AGENTS ANTIPALUDÉENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009141782A1

  公开（公告）日：2009-11-26

  The invention relates to novel tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment

  这项发明涉及新型四氢异喹啉衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括含有其中一种或多种化合物的药物组合物以及它们作为治疗药物的用途。
• [EN] SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF<br/>[FR] BENZOFURANYLES ET BENZOXAZOLYLES SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2015003166A1

  公开（公告）日：2015-01-08

  The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A) : or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  这项发明通常涉及取代苯并呋喃基和取代苯并噁唑基化合物，更具体地涉及一种由结构式（A）表示的化合物：或其药学上可接受的盐，其中变量如本文所定义和描述。该发明还包括合成和使用结构式（A）的化合物，或其药学上可接受的盐或组合物，例如，在癌症（例如，外套细胞淋巴瘤）和其他疾病和疾病的治疗中。
• Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160221994A1

  公开（公告）日：2016-08-04

  The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  本发明通常涉及取代的2,3-二氢苯并呋喃基化合物，更具体地涉及由结构式（I）表示的化合物，或其药学上可接受的盐，在此变量的定义和描述中。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组合物，例如在治疗癌症（例如曼托细胞淋巴瘤）和其他疾病和障碍中。
• Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10399963B2

  公开（公告）日：2019-09-03

  The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  本发明一般涉及取代的苯并呋喃基和取代的苯并恶唑基化合物，特别是结构式 A 所代表的化合物： 或其药学上可接受的盐，其中变量如本文所定义和描述。本发明还包括结构式A化合物或其药学上可接受的盐或组合物的合成和使用，例如用于治疗癌症（如套细胞淋巴瘤）和其它疾病和失调。